Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...

(RTTNews) - Cingulate Inc. (CING) announced it was issued a European patent for lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder. The patent will include up to 30 ...

Cingulate's stock surges over 159% after being granted a European patent for its lead ADHD treatment asset, CTx-1301. CTx-1301 is designed to deliver three timed releases of medication throughout the ...